World's 2nd KRAS Inhibitor Approved For Non-Small Cell Lung Cancer With 80% Efficacy!

More Significant Survival Benefit For Non-Small Cell Lung Cancer Patients Under 55 Years Of Age, Also Using Immunotherapy!

Significant Improvement In Survival For Pancreatic Cancer Patients! A first-Line NALIRIFOX Regimen To Look Forward To!

Frequent CT After Lung Cancer Surgery For Fear Of Recurrence?

The Prerequisite For a Handsome Man: a Healthy Prostate

J. Enzyme Inhib. Med. Chem. | Protac Targeting Aimp2-Dx2: a New Therapy For Lung Cancer